Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2016
The investigators design a multicenter randomized controlled trial to prove that RIF plus ATRA is possibly superior to ATO plus ATRA as consolidation and maintenance treatment for the patients with non-high-risk APL.
Epistemonikos ID: 3acdbbe5a2bb4fa53b765bff2aa5b2dd78b6c02a
First added on: Jan 21, 2022